Group 1: Core Insights - The company plans to issue A-shares at a price of 3.15 yuan per share to raise up to 450 million yuan for working capital and debt repayment, pending shareholder and regulatory approvals [2] - The company is divesting non-core assets and investing in its core business, including a 18 million yuan transfer of a drug license and a 455.56 thousand yuan investment in a related company to expand its moxibustion business [3] - The company reported a revenue of 457 million yuan for the first three quarters of 2025, a year-on-year decline of 31.02%, and a net loss of 97.79 million yuan, prompting strategic asset divestment and increased R&D efforts [4] Group 2: Regulatory and Compliance - The company has had no administrative penalties in the past five years but was ordered to rectify accounting irregularities and non-operating fund usage by the Sichuan Securities Regulatory Bureau in May 2025, with warnings issued to relevant executives [5]

南方财经12月17日电，华神科技(000790.SZ)12月16日公告，公司制药厂拟以1800万元（含税）向四川 滨江药业转让"无烟灸条"药品上市许可及相关技术。与此同时，公司将以455.56万元对主营药用艾灸产 品的上海艾星程科技有限公司进行增资，获得其10%股权。这两项行动共同构成一项复杂的项目合作， 旨在整合"无烟灸条"与滨江药业原有的"药用灸条"产品线。根据协议，在无烟灸条上市许可转让期间， 滨江药业将获得该产品全国总经销权；转让完成后，华神制药厂将继续作为独家生产方。此次交易尚需 股东大会审议批准"。 财务数据显示，公司2025年前三季度实现营业收入4.57亿元，同比下降31.02%；归母净利润亏 损-9778.53万元，同比下降1804.21%。 本次交易的受让方四川滨江药业财务规模较小。截至2025年9月末，其总资产285万元，净资产为-53万 元，前三季度营业收入17万元，净利润亏损71万元。华神科技拟投资的上海艾星程科技是一家2025年10 月新成立的公司，尚未产生营业收入，截至12月3日总资产4100万元，但已录得净利润亏损250万元。交 易定价依据评估报告，标的无形资产评估值为1809万 ...

Core Viewpoint - Huasheng Technology (000790) announced the transfer of its "smokeless moxibustion stick market authorization rights and related technology" to Sichuan Binjiang Pharmaceutical Co., Ltd. for a total amount of 18 million yuan (including tax) [1] Group 1 - The transfer aims to optimize asset allocation and focus on core business areas [1] - The business scale of the smokeless moxibustion stick product has not significantly impacted the company's performance [1] - This collaboration is expected to revitalize the company's existing pharmaceutical resources, optimize product structure, and enhance asset operational efficiency [1] Group 2 - The recovery of funds from this transaction will support the company's core strategic development and subsequent resource integration [1] - The move is intended to further strengthen the company's competitive position in its main business [1]

格隆汇12月16日丨华神科技(000790.SZ)公布，为进一步盘活公司无形资产，提高资产运营效率，同时 整合相关行业优势资源，向核心领域聚焦，稳步提升持续盈利能力，公司于2025年12月15日召开第十三 届董事会第二十七次会议，审议通过了《关于拟对外转让药品上市许可及相关技术暨签署的议案》，同 意公司、华神制药厂与拟合作方签署《项目合作协议》，根据该协议：（1）华神制药厂拟将持有的无 烟灸条（国药准字Z51021978）生产技术及上市许可资质以评估值为基础，经协商作价人民币1800万元 （含税）转让给滨江药业。（2）公司出资455.5556万元投资参股以药用艾灸相关产品运营管理为主营 业务的上海艾星程科技有限公司，取得其10%的股权。 ...

格隆汇12月16日丨华神科技(000790.SZ)公布，为进一步盘活公司无形资产，提高资产运营效率，同时 整合相关行业优势资源，向核心领域聚焦，稳步提升持续盈利能力，公司于2025年12月15日召开第十三 届董事会第二十七次会议，审议通过了《关于拟对外转让药品上市许可及相关技术暨签署 <项目合作协 议> 的议案》，同意公司、华神制药厂与拟合作方签署《项目合作协议》，根据该协议：（1）华神制 药厂拟将持有的无烟灸条（国药准字Z51021978）生产技术及上市许可资质以评估值为基础，经协商作 价人民币1800万元（含税）转让给滨江药业。（2）公司出资455.5556万元投资参股以药用艾灸相关产 品运营管理为主营业务的上海艾星程科技有限公司，取得其10%的股权。 （原标题：华神科技(000790.SZ)：拟转让药品上市许可及相关技术暨签署《项目合作协议》） ...

每经头条（nbdtoutiao）——中标企业频频弃标 大型医疗设备采购有何难言之隐？ （记者 曾健辉） 截至发稿，华神科技市值为24亿元。 每经AI快讯，华神科技（SZ 000790，收盘价：3.9元）12月16日晚间发布公告称，成都华神科技集团股 份有限公司（以下简称"华神科技""公司"）之分公司成都华神科技集团股份有限公司制药厂（以下简 称"华神制药厂"）拟向四川滨江药业有限公司（以下简称"滨江药业"）转让所持有的"无烟灸条上市许 可持有人权益及相关技术"（以下简称"标的产品"或"协议产品"），经交易双方协商一致，标的产品转 让的总金额为人民币1,800万元（含税）。 2025年1至6月份，华神科技的营业收入构成为：医药业占比78.26%，大健康服务占比17.99%，其他业 务占比2.57%，建筑钢结构占比1.06%，医疗器械占比0.12%。 ...

Core Viewpoint - Huasheng Technology (000790.SZ) announced the transfer of its rights and related technology for "smokeless moxibustion sticks" to Sichuan Binjiang Pharmaceutical Co., Ltd. for a total amount of RMB 18 million (including tax) [1] Group 1 - The transfer involves the rights of the product and associated technology [1] - The total transaction amount is RMB 18 million, which indicates a significant business move for Huasheng Technology [1]

Group 1 - The core point of the article is that Huasheng Technology (000790) has signed a project cooperation agreement with a partner, involving the transfer of production technology and licensing rights for smokeless moxibustion sticks for 18 million yuan (including tax) to Binjiang Pharmaceutical [1] - Huasheng Pharmaceutical Factory will continue to provide contract manufacturing services for the transferred products, generating corresponding revenue [1] - The company will invest 4.555556 million yuan to acquire a 10% stake in Shanghai Aixingcheng Technology Co., Ltd., which focuses on the operation and management of medicinal moxibustion-related products [1]